For instance, in patients with type 2 diabetes, the hypotensive effects of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists were significantly associated with a reduction in mortality and cardiorenal events [64]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.